MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos Sells 130,000 Shares of Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) CEO Da Silva Jorge Santos sold 130,000 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the chief executive officer directly owned 2,948,577 shares in the company, valued at approximately $44,464,541.16. The trade was a 4.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link.

Da Silva Jorge Santos also recently made the following trade(s):

• On Tuesday, December 9th, Da Silva Jorge Santos sold 70,000 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $14.49, for a total value of $1,014,300.00.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX traded up $0.04 during midday trading on Wednesday, reaching $14.59. 1,293,485 shares of the company’s stock traded hands, compared to its average volume of 1,743,358. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The company has a market cap of $937.12 million, a P/E ratio of -4.39 and a beta of 1.21. MoonLake Immunotherapeutics has a 1 year low of $5.95 and a 1 year high of $62.75. The company has a fifty day simple moving average of $11.20 and a two-hundred day simple moving average of $36.25.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same quarter in the previous year, the firm earned ($0.56) EPS. Equities analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MLTX. Caitong International Asset Management Co. Ltd grew its position in MoonLake Immunotherapeutics by 22,387.5% in the third quarter. Caitong International Asset Management Co. Ltd now owns 84,553 shares of the company’s stock worth $606,000 after acquiring an additional 84,177 shares during the period. Voleon Capital Management LP purchased a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth $289,000. Verition Fund Management LLC increased its position in shares of MoonLake Immunotherapeutics by 1,059.4% during the 3rd quarter. Verition Fund Management LLC now owns 272,768 shares of the company’s stock worth $1,956,000 after purchasing an additional 249,241 shares during the last quarter. Quarry LP increased its position in shares of MoonLake Immunotherapeutics by 400.1% during the 3rd quarter. Quarry LP now owns 9,001 shares of the company’s stock worth $65,000 after purchasing an additional 7,201 shares during the last quarter. Finally, Prelude Capital Management LLC purchased a new stake in MoonLake Immunotherapeutics in the 3rd quarter valued at about $321,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MLTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MoonLake Immunotherapeutics in a research note on Wednesday, October 8th. Guggenheim dropped their target price on shares of MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 30th. Stifel Nicolaus cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $13.00 target price for the company. in a research report on Monday, September 29th. Royal Bank Of Canada restated a “sector perform” rating and set a $10.00 price target (down from $67.00) on shares of MoonLake Immunotherapeutics in a research report on Monday, September 29th. Finally, Wolfe Research lowered shares of MoonLake Immunotherapeutics from an “outperform” rating to an “underperform” rating in a research note on Tuesday, September 30th. Five equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, MoonLake Immunotherapeutics presently has an average rating of “Hold” and a consensus price target of $30.25.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.